LeMaitre Vascular (NASDAQ:LMAT) Reaches New 1-Year High - What's Next?

Key Points

• Shares hit a new 52-week high, trading as high as $116.50 (last $116.396) on Tuesday with about 7,931 shares changing hands, well above its 50- and 200-day moving averages of $102.43 and $91.59.
• Several brokerages have upgraded or raised targets on LMAT recently, leaving a MarketBeat consensus of "Moderate Buy" with an average price target of $105.80.
• LeMaitre beat quarterly expectations (EPS $0.68 vs. $0.67; revenue $64.45M, +15.7% YoY), set FY2026 guidance of EPS 2.81–3.01, and raised its quarterly dividend to $0.25, though insiders have sold significant stock recently (CEO sold 150,000 shares; insiders sold 215,438 shares in the last 90 days).

LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report)'s share price hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $116.50 and last traded at $116.3960, with a volume of 7931 shares traded. The stock had previously closed at $114.62.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on LMAT. Weiss Ratings upgraded LeMaitre Vascular from a "hold (c+)" rating to a "buy (b-)" rating in a report on Tuesday, March 10th. Barrington Research upped their price objective on LeMaitre Vascular from $95.00 to $105.00 and gave the stock an "outperform" rating in a research report on Thursday, February 26th. Roth Mkm reaffirmed a "buy" rating and set a $117.00 price objective (up from $108.00) on shares of LeMaitre Vascular in a research report on Thursday, February 26th. Citizens Jmp upped their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the stock a "market outperform" rating in a research report on Thursday, February 26th. Finally, Wall Street Zen raised LeMaitre Vascular from a "hold" rating to a "buy" rating in a research report on Saturday, February 21st. Four research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average price target of $105.80.

LeMaitre Vascular Stock Up 2.0%

The firm has a 50-day moving average of $102.43 and a 200 day moving average of $91.59. The company has a debt-to-equity ratio of 0.43, a current ratio of 12.89 and a quick ratio of 10.95. The stock has a market capitalization of $2.68 billion, a price-to-earnings ratio of 46.80, a PEG ratio of 3.30 and a beta of 0.67.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, beating the consensus estimate of $0.67 by $0.01. LeMaitre Vascular had a return on equity of 14.72% and a net margin of 23.13%.The firm had revenue of $64.45 million during the quarter, compared to analysts' expectations of $62.98 million. During the same period in the prior year, the firm posted $0.49 earnings per share. The business's quarterly revenue was up 15.7% compared to the same quarter last year. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, March 26th. Investors of record on Thursday, March 12th were given a dividend of $0.25 per share. This represents a $1.00 annualized dividend and a yield of 0.9%. This is a boost from LeMaitre Vascular's previous quarterly dividend of $0.20. The ex-dividend date of this dividend was Thursday, March 12th. LeMaitre Vascular's payout ratio is currently 39.84%.

Insider Activity at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 150,000 shares of the firm's stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $106.76, for a total value of $16,014,000.00. Following the completion of the sale, the chief executive officer directly owned 1,532,304 shares of the company's stock, valued at $163,588,775.04. This trade represents a 8.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Trent G. Kamke sold 1,044 shares of the firm's stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $110.29, for a total value of $115,142.76. Following the completion of the sale, the insider directly owned 6,677 shares of the company's stock, valued at approximately $736,406.33. The trade was a 13.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 215,438 shares of company stock valued at $23,062,911. Insiders own 9.50% of the company's stock.

Institutional Trading of LeMaitre Vascular

Hedge funds have recently made changes to their positions in the business. Vest Financial LLC lifted its position in shares of LeMaitre Vascular by 60.0% in the third quarter. Vest Financial LLC now owns 56,279 shares of the medical instruments supplier's stock valued at $4,925,000 after buying an additional 21,102 shares during the last quarter. SG Americas Securities LLC acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at approximately $1,101,000. Congress Asset Management Co. lifted its position in shares of LeMaitre Vascular by 5.8% in the fourth quarter. Congress Asset Management Co. now owns 732,331 shares of the medical instruments supplier's stock valued at $59,392,000 after buying an additional 40,065 shares during the last quarter. Public Sector Pension Investment Board lifted its position in shares of LeMaitre Vascular by 15.8% in the third quarter. Public Sector Pension Investment Board now owns 81,211 shares of the medical instruments supplier's stock valued at $7,107,000 after buying an additional 11,092 shares during the last quarter. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of LeMaitre Vascular in the third quarter valued at approximately $6,056,000. 84.64% of the stock is owned by institutional investors and hedge funds.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company's offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre's product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.